Chartwell Investment Partners LLC Takes $1.02 Million Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Chartwell Investment Partners LLC purchased a new stake in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 27,164 shares of the company’s stock, valued at approximately $1,015,000. Chartwell Investment Partners LLC owned about 0.08% of Biohaven Pharmaceutical at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BHVN. Bank of New York Mellon Corp bought a new stake in Biohaven Pharmaceutical during the third quarter worth approximately $2,346,000. Sigma Planning Corp acquired a new position in Biohaven Pharmaceutical during the third quarter worth $561,000. Rhumbline Advisers acquired a new position in Biohaven Pharmaceutical during the third quarter worth $395,000. Gilder Gagnon Howe & Co. LLC acquired a new position in Biohaven Pharmaceutical during the third quarter worth $2,790,000. Finally, New York State Common Retirement Fund acquired a new position in Biohaven Pharmaceutical during the third quarter worth $710,000. 47.76% of the stock is owned by institutional investors.

Several research firms recently issued reports on BHVN. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Monday. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. BidaskClub lowered Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. William Blair reissued an “outperform” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $38.00 price target (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Biohaven Pharmaceutical presently has an average rating of “Buy” and an average target price of $38.17.

In other Biohaven Pharmaceutical news, VP Kimberly Gentile sold 5,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $21.99, for a total value of $109,950.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Robert Berman sold 160,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total value of $4,121,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 439,131 shares of company stock valued at $12,011,701.

Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) opened at $21.10 on Wednesday. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $17.00 and a 1 year high of $39.51.

ILLEGAL ACTIVITY WARNING: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2017/12/06/chartwell-investment-partners-llc-invests-1-02-million-in-biohaven-pharm-bhvn.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply